UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 223

Sortiert nach

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors

European journal of cancer (1990), 2019-06, Vol.114, p.67-75

2019

Link zum Volltext

Verfügbarkeit prüfen

Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis

European journal of cancer (1990), 2018-11, Vol.104, p.188-194

2018

Link zum Volltext

Verfügbarkeit prüfen

High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma

Oncogene, 2016-03, Vol.35 (12), p.1565-1574

2016

Link zum Volltext

Verfügbarkeit prüfen

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma

Annals of oncology, 2012-01, Vol.23 (1), p.46-52

2012

Link zum Volltext

Verfügbarkeit prüfen

Pilot trial of sunitinib therapy in patients with von Hippel–Lindau disease

Annals of oncology, 2011-12, Vol.22 (12), p.2661-2666

2011

Link zum Volltext

Verfügbarkeit prüfen

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

The New England journal of medicine, 2015-11, Vol.373 (19), p.1814-1823

2015

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies

European journal of cancer (1990), 2013-10, Vol.49 (15), p.3169-3175

2013

Link zum Volltext

Verfügbarkeit prüfen

Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy

Annals of oncology, 2011-05, Vol.22 (5), p.1048-1053

2011

Link zum Volltext

Verfügbarkeit prüfen

Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis

Oncogene, 2015-05, Vol.34 (19), p.2450-2460

2015

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma

Annals of oncology, 2017-04, Vol.28 (4), p.804-808

2017

Link zum Volltext

Verfügbarkeit prüfen

MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity

British journal of cancer, 2017-01, Vol.116 (1), p.77-84

2017

Link zum Volltext

Verfügbarkeit prüfen

Osseous Pseudoprogression in Vertebral Bodies Treated with Stereotactic Radiosurgery: A Secondary Analysis of Prospective Phase I/II Clinical Trials

American journal of neuroradiology : AJNR, 2016-02, Vol.37 (2), p.387-392

2016

Link zum Volltext

Verfügbarkeit prüfen

Responses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors

Annals of oncology, 2018-10, Vol.29, p.viii401-viii401

2018

Link zum Volltext

Verfügbarkeit prüfen

Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis

Annals of oncology, 2018-10, Vol.29, p.viii309-viii309

2018

Link zum Volltext

Verfügbarkeit prüfen

Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214

Annals of oncology, 2018-10, Vol.29, p.viii309-viii310

2018

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

The New England journal of medicine, 2018-04, Vol.378 (14), p.1277-1290

2018

Link zum Volltext

Verfügbarkeit prüfen

Idiopathic Thrombocytopenic Purpura Following Successful Treatment of Acute Lymphoblastic Leukemia

Leukemia & lymphoma, 2001, Vol.41 (1-2), p.217-220

2001

Link zum Volltext

Verfügbarkeit prüfen

Mitochondrial DNA copy number in peripheral blood leukocytes and the risk of clear cell renal cell carcinoma

Carcinogenesis (New York), 2015-02, Vol.36 (2), p.249-255

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2018-06, Vol.36 (16), p.1588-1593

2018

Link zum Volltext

Verfügbarkeit prüfen

Acute Pancreatitis Associated with Interferon Alpha Therapy for Chronic Myelogenous Leukemia

Leukemia & lymphoma, 2000, Vol.39 (5-6), p.647-650

2000

Link zum Volltext

Verfügbarkeit prüfen

Joint Association of Genome-Wide Association Study―identified Susceptibility Loci and Dietary Patterns in Risk of Renal Cell Carcinoma Among Non-Hispanic Whites

American journal of epidemiology, 2014-09, Vol.180 (5), p.499-507

2014

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase II study of MK-2206 in comparison with everolimus in refractory renal cell carcinoma.(NCI 8727)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.TPS192-TPS192

2011

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab plus Ipilumab versus Sunitinib in Advanced Renal-Cell Carcinoma

The New England journal of medicine, 2018-04, Vol.378 (14), p.1277

2018

Link zum Volltext

Verfügbarkeit prüfen

A clinical and biological profile to predict risk of development of hypertension in patients with non-clear cell renal cell carcinoma treated with sunitinib

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.4601-4601

2010

Link zum Volltext

Verfügbarkeit prüfen

Schedule modifications and treatment outcomes for sunitinib-related adverse events

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e15115-e15115

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 223

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(188)
Mit Volltextzugriff
(213)

Publikationsform

Artikel
(196)
Buchkapitel
(26)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(77)
Life Sciences & Biomedicine
(74)
Humans
(73)
Male
(54)
Oncology
(52)
Female
(47)
Middle Aged
(42)
Aged
(31)
Adult
(30)
Kidney Neoplasms - Pathology
(25)
Kidney Neoplasms - Drug Therapy
(23)
Treatment Outcome
(23)
Carcinoma, Renal Cell - Drug Therapy
(22)
Biological And Medical Sciences
(21)
Medical Sciences
(21)
Tumors
(21)
Carcinoma, Renal Cell - Pathology
(20)
Aged, 80 And Over
(17)
Renal Cell Carcinoma
(17)
Carcinoma, Renal Cell - Mortality
(16)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors

Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis

High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma

Pilot trial of sunitinib therapy in patients with von Hippel–Lindau disease

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies

Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy

Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma

MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity

Osseous Pseudoprogression in Vertebral Bodies Treated with Stereotactic Radiosurgery: A Secondary Analysis of Prospective Phase I/II Clinical Trials

Responses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors

Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis

Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Idiopathic Thrombocytopenic Purpura Following Successful Treatment of Acute Lymphoblastic Leukemia

Mitochondrial DNA copy number in peripheral blood leukocytes and the risk of clear cell renal cell carcinoma

Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma

Acute Pancreatitis Associated with Interferon Alpha Therapy for Chronic Myelogenous Leukemia

Joint Association of Genome-Wide Association Study―identified Susceptibility Loci and Dietary Patterns in Risk of Renal Cell Carcinoma Among Non-Hispanic Whites

A randomized phase II study of MK-2206 in comparison with everolimus in refractory renal cell carcinoma.(NCI 8727)

Nivolumab plus Ipilumab versus Sunitinib in Advanced Renal-Cell Carcinoma

A clinical and biological profile to predict risk of development of hypertension in patients with non-clear cell renal cell carcinoma treated with sunitinib

Schedule modifications and treatment outcomes for sunitinib-related adverse events

Suchergebnisse filtern